Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations

被引：2

作者：

Liu, Fangfang ^{[1
]}

Yuan, Xun ^{[1
]}

Jiang, Jizong ^{[1
]}

Chu, Qian ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Peoples R China

来源：

IMMUNOTHERAPY | 2020年 / 12卷 / 16期

基金：

中国国家自然科学基金;

关键词：

EGFRmutation; immune checkpoint inhibitors; immunotherapy; NSCLC; PD-L1; LIGAND; 1; EXPRESSION; PD-L1; OPEN-LABEL; 1ST-LINE TREATMENT; EGFR MUTATIONS; ADVANCED NSCLC; T790M STATUS; PHASE-III; NIVOLUMAB; ADENOCARCINOMA;

D O I：

10.2217/imt-2020-0148

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

EGFR-tyrosine kinase inhibitors (EGFR-TKIs) had been regarded as the front-line treatment for advanced non-small-cell lung cancer (NSCLC) patients withEGFRmutations. However, resistance to EGFR-TKIs is inevitable, it remains a major challenge. Immune checkpoint inhibitors (ICIs) had shown superior clinical efficacy in many types of solid tumors, while it exhibited impaired overall efficacy in NSCLC with EGFRmutations. In this review, we will perform a meta-analysis to assess the relationship between the programmed death ligand 1 (PD-L1) expression and clinical benefit of EGFR-TKIs. We also overview the immunotherapy in advanced NSCLC patients withEGFRmutations to investigate the potential biomarkers predicting the ICIs efficiency, and the subgroups that could benefit from ICIs treatment.

引用

页码：1195 / 1207

页数：13

共 78 条

[41]

NCCN, 2020, NCCN Guidelines

[42] PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis [J].

Passiglia, Francesco ;

Bronte, Giuseppe ;

Bazan, Viviana ;

Natoli, Clara ;

Rizzo, Sergio ;

Galvano, Antonio ;

Listi, Angela ;

Cicero, Giuseppe ;

Rolfo, Christian ;

Santini, Daniele ;

Russo, Antonio .

ONCOTARGET, 2016, 7 (15) :19738-19747

[43] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[44] Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma [J].

Rangachari, Deepa ;

VanderLaan, Paul A. ;

Shea, Meghan ;

Le, Xiuning ;

Huberman, Mark S. ;

Kobayashi, Susumu S. ;

Costa, Daniel B. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) :878-883

[45] Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer [J].

Rebuzzi, Sara Elena ;

Leonetti, Alessandro ;

Tiseo, Marcello ;

Facchinetti, Francesco .

IMMUNOTHERAPY, 2019, 11 (12) :993-1003

[46] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[47] Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789 [J].

Riely, G. ;

Hui, R. ;

Carbone, D. ;

Park, K. ;

Carrigan, M. ;

Xu, X. ;

Dang, T. ;

Yang, J. Chih-Hsin .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S494-S494

[48] Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [J].

Rizvi, Hira ;

Sanchez-Vega, Francisco ;

La, Konnor ;

Chatila, Walid ;

Jonsson, Philip ;

Halpenny, Darragh ;

Plodkowski, Andrew ;

Long, Niamh ;

Sauter, Jennifer L. ;

Rekhtman, Natasha ;

Hollmann, Travis ;

Schalper, Kurt A. ;

Gainor, Justin F. ;

Shen, Ronglai ;

Ni, Ai ;

Arbour, Kathryn C. ;

Merghoub, Taha ;

Wolchok, Jedd ;

Snyder, Alexandra ;

Chaft, Jamie E. ;

Kris, Mark G. ;

Rudin, Charles M. ;

Socci, Nicholas D. ;

Berger, Michael F. ;

Taylor, Barry S. ;

Zehir, Ahmet ;

Solit, David B. ;

Arcila, Mina E. ;

Ladanyi, Marc ;

Riely, Gregory J. ;

Schultz, Nikolous ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) :633-+

[49] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[50] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

← 1 2 3 4 5 6 7 8 →